Human papillomavirus: screening and vaccination

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Every year, 500 000 women worldwide are diagnosed with cervical cancer. Currently, there is no doubt that certain types of human papillomavirus (HPV) do act as causative agents of cervical cancer. Nowadays there are more than 150 different types of HPV are known. Certain types of viruses by affecting the epithelium of humans and animals lead to appearance of warts or papillomas, others lead to malignancy of squamous epithelium. The most common HPV types are 16 and 18, cause cervical cancer. Vaccination and screening are the most effective tools for preventing cervical cancer. Preventive vaccines are currently registered and actively used in many countries around the world.

Full Text

Restricted Access

About the authors

Elena Evgen’yevna Roik

Northern State Medical University

Email: roik.elena@gmail.com
postgraduate student, department of obstetrics and gynecology

Aleksey Nikolaevich Baranov

Northern State Medical University

Email: albar@atnet.ru
PhD, DSc, professor, Head of the Department of obstetrics and gynecology

Maksim Vadimovich Usynin

Northern State Medical University

MD, assistant professor, department of obstetrics and gynecology

References

  1. Роговская С. И., Михеева И. В., Шипулина О. Ю., Минкина Г. Н., Минкина Г. Н., Подзолкова Н. М., Радзинский В. Е., Шипулин Г. А. Распространенность папилломавирусной инфекции в России. Эпидемиология и вакцинопрофилактика. 2012; 1: 25-33.
  2. Cutts F. T., Franceschi S., Goldie S., Castellsague X., de Sanjose S., Garnett G., Edmunds W. J., Claeys P., Goldenthal K. L., Harper D. M., Markowitz L. Human papillomavirus and HPV vaccines: a review. Bull World Health Org. 2007; 85: 719-26.
  3. De Villiers E. M., Fauquet C., Broker T. R., Bernard H. U., zur Hausen H. Classification of papillomaviruses. Virology. 2004; 324: 17-27.
  4. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006; 110 (5): 525-41.
  5. Dunne E. F., Unger E. R., Sternberg M., McQuillan G., Swan D. C., Patel S. S., Markwitz L. E. Prevalence of HPV infection among females in the United States. JAMA. 2007; 297: 813-9.
  6. Ferlay J., Shin H. R., Bray F., Forman D., Mathers C., Parkin D. M. Globocan 2008 v 1.2, Cancer Incidence and Mortality Worldwide: IARK CancerBase No 10 [Internet]. Lyon, France: International Agency of Research on Cancer; 2010. [Available at: http://globocan.iarc.fr].
  7. Grabowska A. K., Riemer A. B. The Invisible Enemy-how human papillomaviruses avoid recognition and clearance by the host immune system. Open Virol J. 2012; 6: 249-56.
  8. Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2 (5): 342-50.
  9. Hausen H. Papillomaviruses in human cancer. Appl Pathol. 1987; 5 (1): 19-24.
  10. Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 2009; 384: 260-265.
  11. National Cancer Registry Project (NCRP) Biennial Report. 2007. New Delhi: Indian Council of Medical Research.
  12. Paavonen J., Jenkins D., Bosch F. X., Naud P., Salmeron J., Wheeler C. M., Chow S. N., Apter D. L., Kitchener H. C., Castellsague X., de Carvalho N. S., Skinner S. R., Harper D. M., Hedrick J. A., Jaisamrarn U., Limson G. A., Dionne M., Quint W., Spiessens B., Peeters P., Struyf F., Wieting S. L., Lehtinen M. O., Dubin G. HPV PATRICIA study group. 2007. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369 (9580): 2160-2170 Erratum in: Lancet. 2007; 370 (9596): 1414.
  13. Parkin D. M., Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006; 24 (Suppl 3): S11-25.
  14. Bray F., Lortet-Tieulent J., Znaor A., Brotons M., Poljak M., Arbyn M. Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia. Vaccine. 2013 Dec 31;31 Suppl 7: H32-45. doi: 10.1016/j.vaccine.2013.02.071.
  15. Rogovskaya S.I, Shabalova I.P, Mikheeva I.V, Minkina G.N, Podzolkova N.M, Shipulina O.Y, Sultanov S.N, Kosenko I.A, Brotons M., Buttmann N., Dartell M., Arbyn M., Syrjanen S., Poljak M. Human Papillomavirus Prevalence and Type-Distribution, Cervical Cancer Screening Practices and Current Status of Vaccination Implementation in Russia, the Western Countries of the former Soviet Union, Caucasus Region and Central Asia. Vaccine. 2012.
  16. Fahey M. T., Irwig L., Macaskill P. Meta-analysis of Pap-test accuracy. Am J Epidemiol 1995; 141: 680-9.
  17. Wang K. L. Human papillomavirus and vaccination in cervical cancer. Taiwan J Obstet Gynecol. 2007; 46: 352-62.
  18. Ronco G., Anttila A. Cervical cancer screening in Europe - changes over the last 9 years. Eur J Cancer. 2009 Oct; 45 (15): 2629-31. doi: 10.1016/j.ejca.2009.07.021. Epub 2009 Aug 18.
  19. Anttila A., Ronco G. Working Group on the Registration and Monitoring of Cervical Cancer Screening Programmes in the European Union; within the European Network for Information on Cancer (EUNICE). Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer. 2009 Oct; 45 (15): 2685-708. doi: 10.1016/j.ejca.2009.07.017. Epub 2009 Sep 8.
  20. Anttila A., Nieminen P. Cervical cancer screening programme in Finland. Eur J Cancer. 2000 Nov; 36 (17): 2209-14.
  21. Korfage I. J., Essink-Bot M. L., Daamen R., Mols F., van Ballegooijen M. Women show mixed intentions regarding the uptake of HPV vaccinations in pre-adolescents: a questionnaire study. Eur J Cancer. 2008 Jun; 44 (9): 1186-92. doi: 10.1016/j.ejca. 2008.03.018.
  22. Bosch F. X., Broker T. R., Moscicki A. B., Gillison M. L., Doorbar J., Stern P. L., Stanley M., Arbyn M., Poljak M., Brotons M., Alemany L., Albero G., Diaz M. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013 Dec 31;31 Suppl 7: H1-31.
  23. Sanner K., Wikström I., Strand A., Lindell M., Wilander E. Self-sampling of the vaginal fluid at home combined with high-risk HPV testing. Br J Cancer. 2009 Sep 1; 101 (5): 871-4.
  24. ACOG Practice Bulletin Number 131: Screening for cervical cancer. Obstet Gynecol. 2012 Nov; 120 (5): 1222-38.
  25. Hansena B., Susanne K., Lisen A., Kirsten E. Jensen B., Nygårda M. Human papillomavirus (HPV) vaccination and subsequent sexual behaviour: Evidence from a large survey of Nordic/Vaccine, 2014 3 September; 32 (39): 4945-53.
  26. В. И. Чиссова, В. В. Старинского, Г. В. Петровой. Состояние онкологической помощи населению россии в 2010 году / под. ред. М.: ФГУ «МНИОИ им. П. А. Герцена» Минздравсоцразвития России, 2011; 188.
  27. Махсон А. Н., Сдвижков А. М., Евтягин В. В. и др. Скрининг для выявления рака шейки матки в Москве // Протокол заседания московского общества онкологов (29 марта 2012 г.). http://www.oncology.ru.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Roik E.E., Baranov A.N., Usynin M.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 66759 от 08.08.2016 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия Эл № 77 - 6389 от 15.07.2002 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies